COSTEM 2019 | Haploidentical transplantation for AML with MRD at transplantation

Stefan Ciurea

Stefan Ciurea, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the major findings in his study of haploidentical transplantation for acute myeloid leukemia (AML) patients with measurable residual disease (MRD) at transplantation. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

Share this video